Notably, single B cell screening has various advantages that include requiring relatively few cells and the ability to discover antibodies against challenging targets. The Beacon® single-cell optofluidic system combines a unique optoelectro positioning (OEP) technology with novel microfluidic technology. It can be used to accurately select single cells on a chip, perform multiple single-cell assays, and export target cells based on specific results. The Beacon® optofluidic platform preserves the diversity of B cells, generating high-quality positive hits at an early stage of discovery and avoiding the loss of “good clones.”
Sino Biological offers rapid mouse mAb development service on the Beacon® platform. The screening of thousands of plasma cells can be completed within days. With fast mouse immunization protocols, Sino Biological obtains positive clones as fast as 35 days, which accelerates the process of antibody (drug) discovery. We also offer mouse monoclonal antibody humanization services.